Dr Reddy's CEO On Clogged Semaglutide Pipeline

Dr Reddy's CEO Erez Israeli stated the company expects improved performance in the second half of fiscal year 2026-27 following resolution of supply issues with semaglutide. Israeli said more than 20 companies are expected to compete in the semaglutide generics market. The company has not disclosed a timeline for resolving the supply constraints.

Next story